A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status unconfirmed · Phase 1
Conditions studied: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
In brief
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: * Part A: MPT-0118 dose-escalation * Part B: MPT-0118 dose-escalation in combination with pembrolizumab * Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Key facts
- Study ID
- NCT04859777
- Run by
- Monopteros Therapeutics Inc.
- People needed
- 70
- Starts
- 2021-04-13
- Expected to finish
- 2023-03-01
- Last updated by the study team
- 2021-09-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St. John's Cancer Center — Santa Monica, California, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Columbia University — New York, New York, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.